SOUTH JORDAN, Utah, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today reported that it has completed the acquisition of Cook Medical’s lead management portfolio. The purchase consideration consisted of a cash payment of approximately $210 million and the assumption of certain liabilities. Merit funded the acquisition payment through a combination of cash on hand and borrowings under its long-term credit facility. “We are pleased to ...

Merit Medical Systems, Inc. (MMSI) reported third-quarter 2024 adjusted earnings per share (EPS) of 86 cents, up 21.1% from the year-ago quarter. The bottom line surpassed the Zacks Consensus Estimate by 7.5%.GAAP EPS for the quarter was 48 cents, up 9.1% year over year.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.MMSI’s Revenue DetailsRevenues grossed $339.8 million in the reported quarter, up 7.8% year over year. The metric topped the Zacks Consensus Estimate by 1.4%.Total revenu ...

Merit Medical (MMSI) reported $339.85 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 7.8%. EPS of $0.86 for the same period compares to $0.75 a year ago. View all Key Company Metrics for Merit Medical here>>> The reported revenue represents a surprise of +1.44% over the Zacks Consensus Estimate of $335.02 million. With the consensus EPS estimate being $0.80, the EPS surprise was +7.50%. While investors closely watch year-over-year changes in headline numbe ...

Merit Medical (MMSI) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.80 per share. This compares to earnings of $0.75 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 7.50%. A quarter ago, it was expected that this maker of disposable medical devices would post earnings of $0.88 per share when it actually produced earnings of $0.92, delivering a surprise of 4.55%. Over the last f ...

Exhibit 99.1 1 | --- | --- | --- | |-------|---------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------| | | | | | | Contacts: | | | | PR/Media Inquiries: Sarah Comstock Merit Medical +1-801-432-2864 sarah.comstock@merit.com | Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke – ICR +1-443-213-0509 mike.piccinino@westwicke.com | FOR IMMEDIATE REL ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Merit Medical (MMSI) . This company, which is in the Zacks Medical - Dental Supplies industry, shows potential for another earnings beat.This maker of disposable medical devices has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise f ...

Core Points - Merit Medical Systems, Inc. will release its financial results for Q3 2024 on October 30, 2024, after market close [1] - An investor conference call is scheduled for the same day at 5:00 p.m. Eastern Time [1] Company Overview - Merit Medical Systems, Inc. was founded in 1987 and specializes in the development, manufacture, and distribution of proprietary medical devices for interventional, diagnostic, and therapeutic procedures [3] - The company focuses on key areas such as cardiology, radiology, oncology, critical care, and endoscopy [3] - Merit has a global presence with a sales force and clinical support team of over 700 individuals and employs approximately 7,200 people worldwide [3]

Core Viewpoint - Merit Medical Systems, Inc. (MMSI) has shown strong performance with a 24.7% increase in share price year-to-date, contrasting with a 1.6% decline in the industry and a 20.8% rise in the S&P 500 composite [1] Company Overview - Merit Medical specializes in peripheral and cardiac intervention products aimed at treating cardiac conditions, operating through two segments: Cardiovascular and Endoscopy [2] - The Cardiovascular segment includes a wide range of medical devices for vascular access, while the Endoscopy segment focuses on gastroenterology and pulmonary products [3] Growth Catalysts - The company has enhanced its product offerings through an asset purchase agreement with EndoGastric Solutions, adding the EsophyX Z+ device to its endoscopy portfolio, which is expected to strengthen its market position [5] - Recent product launches include the basixSKY Inflation Device and the Siege Vascular Plug, contributing to the company's growth [6] - For the three months ending June 30, 2024, the Cardiovascular segment accounted for 96.9% of total sales, with total revenue growth of 5.6% reported [7] Financial Performance - The company has outperformed Zacks Consensus Estimates for earnings and revenues, driven by strong performance in both domestic and international markets [8] - The Zacks Consensus Estimate projects a 10% and 11.6% year-over-year improvement in earnings for 2024 and 2025, respectively, with revenues expected to rise to $1.34 billion and $1.44 billion [11]

Core Viewpoint - Merit Medical Systems, Inc. (MMSI) is positioned for growth due to a strong product portfolio and solid second-quarter 2024 performance, despite facing challenges from healthcare industry consolidation and forex volatility [1][2]. Financial Performance - The company has experienced a 26.6% stock price increase over the past six months, outperforming the industry, which declined by 7.8%, while the S&P 500 rose by 9% [2]. - Merit Medical has a market capitalization of $5.62 billion and projects a 12% growth rate over the next five years, with an average earnings surprise of 8.39% over the past four quarters [2]. Q2 Results - The second-quarter 2024 results showed year-over-year growth in both revenue and earnings, with revenue increases across segments and product categories, particularly in the Cardiovascular unit [3]. - The company reported margin expansion, indicating improved profitability [3]. Product Portfolio - Merit Medical has gained momentum through new product launches and acquisitions, including a recent agreement to purchase Cook Medical's lead management portfolio [4]. - Recent product releases include the basixSKY Inflation Device and the Siege Vascular Plug, along with the Bearing nsPVA Express Prefilled Syringe [5]. Research and Development - R&D remains a critical component of Merit Medical's growth strategy, with R&D expenses rising by 0.7% year-over-year to $20.3 million [6]. - The company is focused on innovation, leading to new product introductions and enhancements in existing products [6]. Industry Challenges - The healthcare industry is experiencing higher consolidation, leading to increased pressure on pricing as larger companies seek to reduce costs and eliminate competition [7][8]. - Forex volatility poses risks to Merit Medical's international operations, potentially impacting margins and financial results if foreign currencies decline against the U.S. dollar [9]. Estimate Trends - There is a positive estimate revision trend for 2024, with the Zacks Consensus Estimate for EPS increasing by 0.6% to $3.33 [10]. - The consensus estimate for Q3 2024 revenues is $334.7 million, reflecting a 6.2% increase from the previous year, with EPS expected to improve by 6.7% [10].

Core Viewpoint - Merit Medical Systems, Inc. (MMSI) has signed a definitive asset purchase agreement to acquire Cook Medical's lead management portfolio for approximately $210 million, aiming to enhance its offerings in cardiac intervention solutions [1][5][6]. Company Summary - The acquisition is expected to close in the fourth quarter of 2024, pending customary closing conditions [2]. - Following the announcement, MMSI's stock rose nearly 0.2% to $98.71, reflecting positive market sentiment [3]. - MMSI currently has a market capitalization of $5.75 billion and a return on equity of 15.3%, outperforming the industry average of 10.5% [4]. - The lead management business from Cook Medical generated approximately $37 million in revenues over the last 12 months, with significant sales across various regions [7]. Financial Projections - The acquired assets are projected to contribute revenues of $4 million to $6 million from the closing date through the end of 2024, but may dilute MMSI's previously forecasted adjusted operating margin, net income, and earnings per share during that period [8][9]. - The acquisition is expected to be accretive to adjusted gross and operating margins in 2025 and to adjusted net income and EPS from 2026 onward [9]. - MMSI has updated its revenue guidance for 2024 to a range of $1.339 billion to $1.351 billion, reflecting the impact of the acquisition [13][14]. Industry Context - The cardiac intervention market represents an annual addressable opportunity of over $900 million in the U.S., EMEA, and APAC regions, positioning MMSI favorably within this market [11]. - The deal is anticipated to enhance MMSI's strategy for continuous growth through portfolio expansion, particularly in the high-margin electrophysiology and cardiac rhythm management sectors [10][12].